CAPR - Capricor Therapeutics - 100%+ Short Float of Retail Shares - Long Setup

$CAPR is shaping up for a potential repeat of what we saw in November. Short interest has climbed back above 30% of the float, sentiment around FDA approval has pushed the stock down to levels that seem to reflect a meaningful chance of rejection, and despite the positive data already released, the market is still leaving roughly $8–10/share of upside on the table if approval expectations improve.

With 7 days to cover, any positive update from the upcoming FDA meetings or favorable developments in the Nippon litigation could create the conditions for another sharp move higher.

ADCOMM is next week

PDUFA - August 22

Nippon Lawsuit Update - August

Lots of positive catalysts and the lease of 171,000 square feet with over a year free rent is huge for ramp up for distribution and production.

Price Target: $35

Current position: 275,000 Shares (Covered half with $35 calls)